RET rs121913526: MEN2A and Thyroid Cancer Predisposition
The genetic variant rs121913526 is a rare missense mutation in the RET proto-oncogene known at the protein level as p.Cys634Arg. It is strongly associated with an inherited cancer predisposition syndrome known as Multiple Endocrine Neoplasia Type 2A (MEN2A) and familial medullary thyroid carcinoma. Carrying this variant leads to abnormal activation of cell signaling pathways that regulate endocrine tissue growth.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| TT | The TT genotype represents the standard reference sequence without the p.Cys634Arg substitution. Individuals with this genotype do not carry this specific high-risk alteration for MEN2A. General population-level cancer risks remain unchanged. | Informational |
| CT | The CT genotype indicates heterozygosity for the pathogenic missense change p.Cys634Arg in the RET gene. Because MEN2A exhibits autosomal dominant inheritance, carrying a single altered allele significantly predisposes to medullary thyroid carcinoma and related endocrine tumors. Clinical-grade diagnostic confirmation and professional genetic counseling are advised. | Higher attention |
| CC | The CC genotype represents homozygous inheritance of the p.Cys634Arg substitution, which is extraordinarily rare and seldom observed in human populations. Both copies of the gene carry the pathogenic activation signal, conveying a severe predisposition to endocrine neoplasia. Immediate genetic and medical evaluation is essential to verify findings and assess endocrine health. | Higher attention |
What Is rs121913526 and Where Is It Located?
The variant rs121913526 is a single-nucleotide alteration located within the RET proto-oncogene on chromosome 10. Specifically, this change corresponds to a thymine-to-cytosine transition at nucleotide position 1900 (c.1900T>C) in standard transcripts. This coding change alters codon 634, substituting the amino acid cysteine with an arginine residue (p.Cys634Arg). In genomic databases such as ClinVar and dbSNP, this position resides within the extracellular cysteine-rich domain of the receptor. Because cysteines in this domain normally participate in tightly regulated intramolecular disulfide bonds, swapping a cysteine for an arginine disrupts normal conformation. This leads to ligand-independent homodimerization and constitutive tyrosine kinase activity, prompting cells to divide uncontrollably.
The Biological Role of the RET Proto-Oncogene
The RET gene encodes a receptor tyrosine kinase that plays an essential role during human embryonic development and tissue maintenance. In normal physiology, the RET receptor sits across the cell membrane in neural crest-derived lineages, including the sympathetic and parasympathetic nervous systems, enteric neurons, and calcitonin-producing neuroendocrine cells of the thyroid gland known as C-cells. RET requires interaction with specific glial cell line-derived neurotrophic factor ligands and coreceptors to activate downstream signaling pathways that control cell proliferation, migration, and survival. Germline gain-of-function variants like those at codon 634 lock the receptor in a persistently active state, bypassing normal growth controls and driving the proliferation of endocrine tissues.
Disease Associations and Strength of Evidence
Variant rs121913526 has extensive clinical documentation and is classified in ClinVar as pathogenic for Multiple Endocrine Neoplasia Type 2A (MEN2A) and familial medullary thyroid carcinoma (FMTC). Decades of pedigree studies, published guidelines from the American Thyroid Association, and oncological registries demonstrate that mutations at codon 634 confer a high penetrance of medullary thyroid carcinoma, frequently occurring early in life. In addition to medullary thyroid cancer, carriers are at elevated risk for pheochromocytomas (adrenal gland tumors) and hyperparathyroidism. Published literature frequently highlights p.Cys634Arg as one of the most clinically aggressive codon 634 substitutions, leading to earlier tumor onset and higher penetrance across affected family branches.
How Common Is This Variant Across Populations?
Across broad global populations, rs121913526 is exceptionally rare. In major population repositories such as the Genome Aggregation Database (gnomAD), the alternate C allele appears at a frequency well below 0.0001 (less than 1 in 10,000 individuals). It does not represent a common benign polymorphism; rather, it is maintained primarily as a rare familial or de novo pathogenic variant. Certain regional studies and epidemiological reviews across the Mediterranean Basin and East Asia have documented rs121913526 in specific multi-generational pedigrees, in some instances reflecting localized founder effects. Outside of affected pedigrees and clinical cohorts presenting with endocrine neoplasia, the variant is virtually absent.
Understanding What You Can and Cannot Do With This Information
Genetic findings from direct-to-consumer screening or raw genetic data must be treated with caution, as automated arrays can generate false-positive calls on rare pathogenic alleles. Finding an rs121913526 variant does not constitute a formal medical diagnosis, nor does its absence guarantee immunity from endocrine tumors. If this variant is flagged on an unvalidated test or an individual has a family history of medullary thyroid cancer or pheochromocytoma, the crucial next step is clinical-grade Sanger or targeted NGS confirmation ordered by a healthcare provider. Clinical management for confirmed carriers involves specialized endocrine monitoring and clinical surveillance protocols overseen by multidisciplinary genetics and oncology teams.
How common is this variant?
Variant rs121913526 is exceedingly rare globally, with an allele frequency under 0.0001 in population reference databases like gnomAD, though it appears as an established founder mutation in specific multigenerational MEN2A pedigrees.
Frequently asked questions
Does carrying the rs121913526 variant mean I have cancer?
No, carrying the variant indicates an inherited genetic predisposition, not an active diagnosis of cancer. While it strongly increases the statistical risk for developing medullary thyroid carcinoma and pheochromocytoma, specific medical testing is required to assess tumor presence. Any suspected result should be confirmed through a clinical laboratory.
How is MEN2A inherited in families?
Multiple Endocrine Neoplasia Type 2A is inherited in an autosomal dominant pattern. This means an individual who carries one copy of the pathogenic variant has a 50% chance of passing it on to each biological child. It can also occasionally arise as a new, spontaneous genetic alteration (de novo).
Can commercial consumer DNA kits accurately detect rs121913526?
Consumer genotyping microarrays are designed to assess common genetic variations and frequently produce false positives when calling ultra-rare disease-associated mutations. Any raw-data discovery of rs121913526 should be considered unconfirmed until validated by clinical-grade diagnostic sequencing ordered by a physician.
What is the difference between familial and sporadic medullary thyroid cancer?
Familial medullary thyroid cancer occurs when a pathogenic variant such as rs121913526 is inherited in every cell of the body through the germline, frequently affecting multiple family members. Sporadic cases, in contrast, arise from non-inherited mutations that occur only inside a single thyroid tumor cell later in life.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121913526?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29